Impact of Topical Interventions on the Vaginal Microbiota and Metabolome in Postmenopausal Women
Authors: Sujatha Srinivasan, Xing Hua, Michael C. Wu, Sean Proll, D. J. Valint, Susan D. Reed, Katherine A. Guthrie, Andrea Z. LaCroix, Joseph C. Larson, Robert Pepin, Shalender Bhasin, Daniel Raftery, David N. Fredricks, Caroline M. Mitchell
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Postmenopausal women with genitourinary symptoms of menopause are often prescribed vaginal estradiol or moisturizer for symptom improvement, but the impact of these treatments on the local microenvironment is poorly understood. <h3>Objective</h3> To compare changes in the vaginal microbiota, metabolome, and pH among women using low-dose vaginal estradiol tablet or low pH moisturizer gel for 12-weeks vs low pH placebo. <h3>Design, Setting, and Participants</h3> This is a post hoc prespecified secondary analysis of a 12-week multicenter randomized clinical trial among postmenopausal women with moderate to severe genitourinary symptoms. Women were enrolled between April 2016 and February 2017; final follow-up visits occurred in April 2017. Data were analyzed from November 2018 to July 2021. <h3>Interventions</h3> Ten-μg vaginal estradiol plus placebo gel vs placebo tablet plus vaginal moisturizer vs dual placebo. <h3>Main Outcomes and Measures</h3> The main outcome measures were changes in the diversity and composition of the vaginal microbiota, changes in the metabolome, and pH. <h3>Results</h3> Of 302 postmenopausal women from the parent trial, 144 women (mean [SD] age, 61 [4] years) were included in this analysis. After 12 weeks, the microbiota was dominated with<i>Lactobacillus</i>and<i>Bifidobacterium</i>communities among 36 women (80%) in the estradiol group, compared with 16 women (36%) using moisturizer and 13 women (26%) using placebo (<i>P</i> &lt; .001). The composition of vaginal fluid metabolites also varied after 12-weeks among women in the estradiol group with significant changes in 90 of 171 metabolites measured (53%) (<i>P</i> &lt; .001), including an increase in lactate. The 12-week pH among women in the estradiol group was lower vs placebo (median [IQR] pH, 5 [4.5-6.0] vs 6 [5.5-7.0];<i>P</i> = .005) but not the moisturizer group vs placebo (median [IQR] pH, 6 [5.5-6.5];<i>P</i> = .28). There was a decrease in pH from baseline to 12-weeks within the moisturizer (median [IQR] pH, 7 [6.0-7.5] vs 6 [5.5-6.5];<i>P</i> &lt; .001) and placebo (median [IQR] pH, 7 [7.0-7.5] vs 6 [5.5-7.0];<i>P</i> &lt; .001) groups. Women with high-diversity bacterial communities at baseline exhibited greater median change in pH compared with women with low-diversity communities (median [IQR] change, −1 [−2 to −0.5] vs −0.3 [−1.1 to 0],<i>P</i> = .007). <h3>Conclusions and Relevance</h3> This secondary analysis of a randomized clinical trial found that use of vaginal estradiol tablets resulted in substantial changes in the vaginal microbiota and metabolome with a lowering in pH, particularly in women with high-diversity bacterial communities at baseline. Low pH moisturizer or placebo did not significantly impact the vaginal microbiota or metabolome despite lowering the vaginal pH. Estradiol use may offer additional genitourinary health benefits to postmenopausal women. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT02516202